Coherus Biosciences Stock Short Ratio

CHRS Stock

USD 1.10 0.28 34.15%

Coherus BioSciences fundamentals help investors to digest information that contributes to Coherus BioSciences' financial success or failures. It also enables traders to predict the movement of Coherus Stock. The fundamental analysis module provides a way to measure Coherus BioSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coherus BioSciences stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Coherus BioSciences Company Short Ratio Analysis

Coherus BioSciences' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Short Ratio

Short Interest

Average Trading Volume

More About Short Ratio | All Equity Analysis

Current Coherus BioSciences Short Ratio

11.95 X

Most of Coherus BioSciences' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coherus BioSciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Coherus Short Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Coherus BioSciences is extremely important. It helps to project a fair market value of Coherus Stock properly, considering its historical fundamentals such as Short Ratio. Since Coherus BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Coherus BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Coherus BioSciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Capital Surpluse	Short Long Term Debt	Intangible Assets	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.22	-0.32	0.29	-0.68	0.51	0.76	0.25	0.82	0.99	-0.04	0.77	0.73	0.09	-0.12	0.81	-0.69	0.32	0.95	0.9	0.82	0.41
Total Stockholder Equity	0.22		0.04	-0.79	0.41	-0.18	-0.28	-0.44	-0.32	0.3	-0.01	-0.18	-0.45	0.96	0.5	-0.14	0.07	-0.66	0.23	0.38	0.61	-0.67
Current Deferred Revenue	-0.32	0.04		-0.49	0.42	0.16	-0.44	-0.21	-0.35	-0.34	0.91	-0.35	-0.4	0.03	0.2	-0.51	0.61	-0.24	-0.44	-0.38	-0.3	-0.25
Net Debt	0.29	-0.79	-0.49		-0.75	0.25	0.69	0.66	0.71	0.23	-0.3	0.54	0.82	-0.81	-0.63	0.59	-0.53	0.75	0.29	0.18	-0.12	0.78
Retained Earnings	-0.68	0.41	0.42	-0.75		-0.64	-0.81	-0.45	-0.89	-0.63	0.16	-0.93	-0.88	0.56	0.49	-0.93	0.89	-0.65	-0.61	-0.48	-0.26	-0.67
Accounts Payable	0.51	-0.18	0.16	0.25	-0.64		0.54	-0.03	0.55	0.43	0.31	0.75	0.45	-0.34	-0.07	0.6	-0.45	0.48	0.3	0.21	0.07	0.55
Net Receivables	0.76	-0.28	-0.44	0.69	-0.81	0.54		0.25	0.94	0.72	-0.16	0.71	0.9	-0.34	-0.58	0.75	-0.68	0.8	0.74	0.69	0.4	0.74
Short Term Investments	0.25	-0.44	-0.21	0.66	-0.45	-0.03	0.25		0.41	0.23	-0.02	0.35	0.53	-0.51	-0.28	0.4	-0.31	0.09	0.2	0.21	0.06	0.29
Total Liab	0.82	-0.32	-0.35	0.71	-0.89	0.55	0.94	0.41		0.78	-0.04	0.78	0.98	-0.42	-0.57	0.81	-0.71	0.74	0.79	0.7	0.46	0.72
Total Current Assets	0.99	0.3	-0.34	0.23	-0.63	0.43	0.72	0.23	0.78		-0.06	0.71	0.69	0.18	-0.11	0.78	-0.68	0.24	0.96	0.94	0.88	0.32
Short Term Debt	-0.04	-0.01	0.91	-0.3	0.16	0.31	-0.16	-0.02	-0.04	-0.06		-0.12	-0.1	-0.07	0.02	-0.26	0.42	-0.09	-0.15	-0.12	-0.09	-0.11
Common Stock	0.77	-0.18	-0.35	0.54	-0.93	0.75	0.71	0.35	0.78	0.71	-0.12		0.73	-0.37	-0.16	0.96	-0.87	0.47	0.63	0.5	0.35	0.61
Property Plant Equipment	0.73	-0.45	-0.4	0.82	-0.88	0.45	0.9	0.53	0.98	0.69	-0.1	0.73		-0.53	-0.61	0.78	-0.68	0.76	0.73	0.62	0.37	0.76
Net Tangible Assets	0.09	0.96	0.03	-0.81	0.56	-0.34	-0.34	-0.51	-0.42	0.18	-0.07	-0.37	-0.53		0.51	-0.3	0.22	-0.65	0.15	0.31	0.55	-0.68
Good Will	-0.12	0.5	0.2	-0.63	0.49	-0.07	-0.58	-0.28	-0.57	-0.11	0.02	-0.16	-0.61	0.51		-0.2	0.31	-0.68	-0.19	-0.23	0.08	-0.33
Capital Surpluse	0.81	-0.14	-0.51	0.59	-0.93	0.6	0.75	0.4	0.81	0.78	-0.26	0.96	0.78	-0.3	-0.2		-0.94	0.43	0.74	0.61	0.48	0.56
Short Long Term Debt	-0.69	0.07	0.61	-0.53	0.89	-0.45	-0.68	-0.31	-0.71	-0.68	0.42	-0.87	-0.68	0.22	0.31	-0.94		-0.39	-0.66	-0.57	-0.43	-0.4
Intangible Assets	0.32	-0.66	-0.24	0.75	-0.65	0.48	0.8	0.09	0.74	0.24	-0.09	0.47	0.76	-0.65	-0.68	0.43	-0.39		0.3	0.21	-0.13	0.87
Long Term Debt Total	0.95	0.23	-0.44	0.29	-0.61	0.3	0.74	0.2	0.79	0.96	-0.15	0.63	0.73	0.15	-0.19	0.74	-0.66	0.3		0.92	0.89	0.33
Net Invested Capital	0.9	0.38	-0.38	0.18	-0.48	0.21	0.69	0.21	0.7	0.94	-0.12	0.5	0.62	0.31	-0.23	0.61	-0.57	0.21	0.92		0.89	0.19
Net Working Capital	0.82	0.61	-0.3	-0.12	-0.26	0.07	0.4	0.06	0.46	0.88	-0.09	0.35	0.37	0.55	0.08	0.48	-0.43	-0.13	0.89	0.89		-0.1
Capital Stock	0.41	-0.67	-0.25	0.78	-0.67	0.55	0.74	0.29	0.72	0.32	-0.11	0.61	0.76	-0.68	-0.33	0.56	-0.4	0.87	0.33	0.19	-0.1

Click cells to compare fundamentals

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Competition

Predict Coherus BioSciences

Coherus Price To Sales Ratio

Price To Sales Ratio

1.16

At this time, Coherus BioSciences' Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Coherus BioSciences has a Short Ratio of 11.95 times. This is 206.41% higher than that of the Biotechnology sector and 61.27% higher than that of the Health Care industry. The short ratio for all United States stocks is 198.75% lower than that of the firm.

Coherus Short Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coherus BioSciences' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics of similar companies.

Coherus BioSciences is currently under evaluation in short ratio category among its peers.

Coherus BioSciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.3B	1.2B	1.2B	614.8M	313.6M	518.3M
Enterprise Value	1.3B	1.1B	1.2B	1.0B	691.5M	539.3M

Coherus BioSciences Institutional Holders

Institutional Holdings refers to the ownership stake in Coherus BioSciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Coherus BioSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Coherus BioSciences' value.

		Shares
Cm Management, Llc	2024-09-30	2 M
Cam Group Holding A/s	2024-06-30	1.9 M
Tang Capital Management Llc	2024-06-30	1.1 M
Tejara Capital Ltd	2024-06-30	1 M
Jacobs Levy Equity Management, Inc.	2024-06-30	1 M
Charles Schwab Investment Management Inc	2024-09-30	964.3 K
Los Angeles Capital Management Llc	2024-09-30	930.1 K
Macquarie Group Ltd	2024-06-30	900 K
Northern Trust Corp	2024-09-30	896.7 K
Blackrock Inc	2024-06-30	11.8 M
Vanguard Group Inc	2024-06-30	10.6 M

Coherus Fundamentals

	Return On Equity	-16.57
	Return On Asset	-0.14
	Profit Margin	(0) %
	Operating Margin	(0.09) %
	Current Valuation	298.92 M
	Shares Outstanding	115.21 M
	Shares Owned By Insiders	1.39 %
	Shares Owned By Institutions	70.09 %
	Number Of Shares Shorted	31.51 M
	Price To Earning	4.22 X
	Price To Book	73.19 X
	Price To Sales	0.42 X
	Revenue	257.24 M
	Gross Profit	(58.4 M)
	EBITDA	(193.94 M)
	Net Income	(237.89 M)
	Cash And Equivalents	275.48 M
	Cash Per Share	3.54 X
	Total Debt	480.84 M
	Current Ratio	3.17 X
	Book Value Per Share	(0.76) X
	Cash Flow From Operations	(174.88 M)
	Short Ratio	11.95 X
	Earnings Per Share	(0.09) X
	Target Price	6.5
	Number Of Employees	235
	Beta	0.69
	Market Capitalization	126.73 M
	Total Asset	629.6 M
	Retained Earnings	(1.58 B)
	Working Capital	143.86 M
	Current Asset	197.39 M
	Current Liabilities	106.02 M
	Net Asset	629.6 M

About Coherus BioSciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC